Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX RTU versus HEPARIN LOCK FLUSH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX RTU versus HEPARIN LOCK FLUSH.
ANGIOMAX RTU vs HEPARIN LOCK FLUSH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates (fibrinogen, factor V, VIII, XIII, and protein C).
Heparin potentiates the activity of antithrombin III, inactivating thrombin and activated factor X (FXa), thereby preventing fibrin formation and thrombus propagation.
1 mg/kg intravenous bolus, followed by 0.15 mg/kg/min continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention (PCI). For patients with heparin-induced thrombocytopenia (HIT) undergoing PCI, bolus 0.75 mg/kg, then 1.75 mg/kg/hour infusion for 4 hours.
10-100 units/mL solution, 1-2 mL flush intravascularly after each catheter use or daily when catheter is not in use; typical adult dose: 10-100 units per flush.
None Documented
None Documented
The terminal elimination half-life of bivalirudin is approximately 25 minutes in patients with normal renal function. In patients with moderate to severe renal impairment, the half-life is prolonged (e.g., up to 1 hour in patients with creatinine clearance <30 mL/min, and up to 3-4 hours in dialysis-dependent patients). This is clinically relevant for dosing adjustments and monitoring of anticoagulation.
Terminal elimination half-life approximately 1-2 hours (mean 1.5 hours) at therapeutic doses; increases with dose; in renal failure, half-life prolonged up to 3-5 hours; clinical note: duration of effect short due to rapid clearance, requiring continuous infusion or frequent dosing.
Bivalirudin is cleared by a combination of renal elimination (approximately 20% unchanged in urine) and proteolytic cleavage (hepatic metabolism and other proteases). Renal clearance accounts for about 20% of total clearance. Fecal excretion is negligible (<1%).
Primarily renal via glomerular filtration and tubular secretion; about 50% excreted unchanged in urine; remainder metabolized in the liver and reticuloendothelial system (heparinase); fecal elimination negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant